• Publications
  • Influence
The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
The QIDS-SR(16) has highly acceptable psychometric properties, which supports the usefulness of this brief rating of depressive symptom severity in both clinical and research settings. Expand
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected. Expand
A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.
Although about half of patients with chronic forms of major depression have a response to short-term treatment with either nefazodone or a cognitive behavioral-analysis system of psychotherapy, the combination of the two is significantly more efficacious than either treatment alone. Expand
Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder
The results suggest that ion channelopathies may be involved in the pathogenesis of bipolar disorder and found further support for the previously reported CACNA1C. Expand
Scientific Foundations of Cognitive Theory and Therapy of Depression
Although there are dozens of books on cognitive therapy of depression, a majority are edited volumes and relatively few are distinguished by the comprehensive mastery of the material and clarity ofExpand
Increased Amygdala and Decreased Dorsolateral Prefrontal BOLD Responses in Unipolar Depression: Related and Independent Features
Depressed individuals also display decreased relationships between amygdala and DLPFC activity, potentially signifying decreased functional relationships among these structures, though these may reflect separate mechanisms. Expand
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Remission rates were significantly higher with venlafaxine than with an SSRI and the difference between SSRIs and placebo reached significance at week 4, and were not dependent on any one study or the definition of remission. Expand
Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
An independent association of comorbid anxiety with greater severity and impairment in bipolar disorder patients was demonstrated, highlighting the need for greater clinical attention to anxiety in this population, particularly for enhanced clinical monitoring of suicidality. Expand
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant, suggesting any one of the medications in the study provided a reasonable second-step choice for patients with depression. Expand
Medication augmentation after the failure of SSRIs for depression.
Augmentation of citalopram with either sustained-release bupropion or buspirone appears to be useful in actual clinical settings, including a greater reduction in the number and severity of symptoms and fewer side effects and adverse events. Expand